Биотехнологическая компания Incyte завершила фазу консолидации
Коррекция цены часто определяется как резкое снижение стоимости, когда график резко опускается после фазы роста.
Incyte
Price: 105.39Company and Business Model
Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for oncology and other serious diseases. Its core products include Jakafi, a treatment for certain blood disorders, and other investigational therapies targeting various cancers. The company generates revenue mainly from product sales and collaborations with other pharmaceutical firms.
Investment Profile
The investment profile of Incyte is more aligned with growth investors, given its focus on innovative therapies and potential for future revenue increases. However, the current market conditions and performance metrics suggest a cautious approach. The stock may appeal to those with a medium to long investment horizon, prioritizing potential capital appreciation over immediate income. Liquidity is moderate, suitable for investors with basic to advanced experience.
Fundamental metrics (experimental)
- EPS (TTM) — earnings per share for the last 12 months, $
- 7.30 OK
- Revenue QoQ — quarter-over-quarter revenue growth
- -15.5% ↓
- EPS surprise
- 31.2% better than expected
- 20d volatility
- 2.0% stable
FMP / FinFeed data updated:
2026-06-09
Forecast impact
positive
Target Raised
· H.C. Wainwright
· valid until 2026-07-10
· updated 2026-06-11
Target
+32.8%
target fill 75.3%
Reaction
D5 pending · D10 pending
fresh confirmed
·
market trust
Impact
Potential +6
·
Risk -3
up to 30 days or until target is reached
Reco: Buy
Potential: 77
Risk: 40
Updated: 2026-06-11 05:32
How recommendation works
Why AI thinks so:
Strong EPS surprise, but revenue decline raises concerns.
Track in portfolio
Price chart
AI recommendation
Analyst forecast
Calendar event
Positive signal
Negative signal
Neutral / update
Hold / informational
B My buy
S My sell
AI recommendation changes
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-06-05 02:40 | Sell | Buy | Mixed signals; revenue decline raises caution. |
| 2026-06-03 02:43 | Hold | Sell | Weak fundamentals and negative momentum raise significant concerns. |
| 2026-05-24 02:42 | Sell | Hold | Weak fundamentals and mixed momentum signal caution. |
Analyst forecasts
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-06-10 11:11 | H.C. Wainwright | Target Raised | — → 140 | 103.23 |
| 2026-06-09 13:11 | Stifel Nicolaus | Update | — → 123 | 103.07 |
| 2026-06-08 18:53 | Oppenheimer | Target Raised | 90 → 107 | 100.64 |